罗特西普在输血依赖的低危骨髓增生异常综合征患者中的真实世界经验
这项多中心回顾性研究纳入98例红细胞刺激剂(ESA)治疗失败后输血依赖的低危骨髓增生异常综合征(LR-MDS)患者,报告罗特西普的疗效与安全性。完成24周随访的患者中44.3%获得持续超过8周的不输血独立,高于MEDALIST试验的38%;因不良事件停药比例与MEDALIST相当。罗特西普缓解和少于两种突变独立预测更长的总生存。
要点
- 完成24周随访者中44.3%获持续>8周的不输血独立,MEDALIST试验为38%。
- 所有缓解均在罗特西普开始后8个月内出现,许多缓解持久,高输血负担组亦如此。
- 罗特西普缓解和少于两种突变独立预测更长的总生存。
核心结论
- 罗特西普在真实世界中用于ESA治疗失败的输血依赖低危MDS患者,安全性和有效性得到确认。
- 作者认为阳性结果可能归因于本研究纳入了输血需求较低的患者。
研究设计与样本
- 多中心回顾性研究,纳入98例ESA治疗失败后接受罗特西普治疗的输血依赖低危MDS患者。
主要发现
- 因不良事件停用罗特西普的患者比例与MEDALIST研究报告相当。
- 完成24周随访的患者中44.3%获得持续超过8周的不输血独立,MEDALIST试验为38%。
- 所有缓解均在罗特西普开始后8个月内出现,许多缓解持久,高输血负担患者组亦如此。
- 罗特西普缓解和少于两种突变独立预测更长的总生存。
关键数值与推荐
- 完成24周随访的患者中44.3%获得持续超过8周的不输血独立,MEDALIST试验为38%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Luspatercept has been approved for the treatment of anaemia in transfusion-dependent (TD) patients with lower risk (LR) myelodysplastic syndromes (MDS) after erythroid-stimulated agent (ESA) failure, according to the results of the MEDALIST trial. In this multicentre retrospective study, we report efficacy and safety data of luspatercept administered in 98 TD LR-MDS patients after ESA failure. The percentage of patients that stopped luspatercept due to adverse events was comparable to that reported in the MEDALIST study. Furthermore, we observed that 44.3% patients who had completed 24 weeks of follow-up achieved transfusion independence lasting longer than 8 weeks, compared to 38% in the MEDALIST trial. These positive results may be attributed to the inclusion of patients with lower transfusion needs in our study. All responses were observed within 8 months since luspatercept onset and many were long-lasting, even in the high-transfusion burden patient group. In addition, response to luspatercept and the presence of less than two mutations independently predicted for longer overall survival. Overall, our results confirm luspatercept's safety and efficacy in TD LR-MDS patients who have experienced ESA failure in a real-world setting.
引用
- Bouchla A, Papageorgiou SG, Kotsianidis I, et al. Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients. Br J Haematol. 2025. PMID: 40325906. doi:10.1111/bjh.20102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。